Ive been reading up on this stock, trading at .68 as of now. CytRx is working on bringing its flagship candidate, aldoxorubicin, to the market. While this is still a while off, the recent Phase 3 clinical trial yielded exceptional results, showing that there is tremendous value in the treatment. At the moment, CYTR has a market cap of around 116.02 million. In the world of oncology, that's pennies my friends. If a competitor wanted to get an exceptional deal on the assets owned by CYTR, that competitor would have to move quickly. After all, if they wait until the next milestone, the stock could shoot up in value, leading to a larger price for anyone interested. Not sure if i should buy in, thoughts?
Submitted June 23, 2017 at 10:37PM by mootman445 http://ift.tt/2s1bEl3
No comments:
Post a Comment